Assessment of gastric cancer risk due to CDH1 P/LP variants is complex, and the onus is on clinicians to correctly interpret individual cancer risk, because risks of both missed diagnoses and overtreatment can be severe.9 This evidence concerns the gene CDH1 and gastric cancer.